Table 1. Side effects reported in different studies in the treatment of non-focal human brucellosis.

Regimen	N° of studies [references]	N° patients	Light to moderate side effects (%)	Serious side effects (%)*
Tetracycline + streptomycin	2 [8], [10]	55	8 (14.5%)	1 (1.8%)
Doxycycline + streptomycin (15 days)	8 [10], [17], [18], [20], [24], [25], [27], [28]	591	98/551 (17.8%)	5 (0.8%)
Doxycycline + streptomycin (21 days)	3 [11], [25], [26]	135	15/91 (16.5%)	0
Doxycycline (30 days)+ gentamicin	2 [31], [32]	108	43 (39.8%)	0
Doxycycline (45 days)+ gentamicin	3 [27], [31], [32]	187	60 (32.1%)	0
Doxycycline (≥56 days)+ gentamicin	1 [28]	82	25 (30.5%)	0
Triple therapy	1 [16]	110	6 (5.5%)	0
Doxycycline + rifampicin (28–30 days)	2 [8], [25]	83	1/18 (5.6%)	0
Doxycycline + rifampicin (42–45 days)	12 [10], [11], [17]–[22], [25], [26], [36], [37]	482	103/406 (25.4%)	6 (1.2%)
Doxycycline + rifampicin (≥56 days)	3 [16], [38], [39]	224	14/171 (8.2%)	2 (0.9%)
Rifampicin + cotrimoxazole	1 [42]	140	----------	7 (5%)
Tetracycline + cotrimoxazole	1 [42]	140	----------	2 (1.4%)
Rifampicin + ciprofloxacin	2 [21], [38]	82	4 (4.9%)	0
Rifampicin + ofloxacin	4 [19], [22], [26], [37]	114	14/87 (16.1%)	1(0.9%)
Doxycycline + quinolone	1 [38]	55	9 (16.4%)	0
Cotrimoxazole	1 [25]	64	----------	2 (3.1%)
Doxycycline	1 [25]	71	----------	1 (1.4%)
Quinolones	1 [50]	16	7 (43.7%)	0